A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

~29 mi. (Guadalajara, Mexico, +144 more cities)

Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0610)

Clear Cell Renal Cell Carcinoma

belzutifan, +3 more drugs

immunotherapy, +1 more type

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

~29 mi. (Guadalajara, Mexico, +356 more cities)

Hospital Civil de Guadalajara Fray Antonio Alcalde

HER2 Positive

Invasive Breast Carcinoma

fam-trastuzumab deruxtecan

targeted therapy

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

~29 mi. (Guadalajara, Mexico, +172 more cities)

Actualidad Basada en la Investigación del Cáncer

RET Fusion

Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

~29 mi. (Guadalajara, Mexico, +158 more cities)

Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0500)

Non-Small Cell Lung Carcinoma

olaparib, +4 more drugs

chemotherapy, +3 more types

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

~29 mi. (Guadalajara, Mexico, +122 more cities)

Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0401)

Small Cell Lung Carcinoma

etoposide, +5 more drugs

chemotherapy, +3 more types

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

~29 mi. (Guadalajara, Mexico, +137 more cities)

Onco-Hematologia de Occidente ( Site 0716)

Skin Squamous Cell Carcinoma

pembrolizumab

immunotherapy

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients

~29 mi. (Guadalajara, Mexico, +163 more cities)

Investigational Site Number :4840004

CEACAM5 Expression

Non-Squamous Non-Small Cell Lung Carcinoma

tusamitamab ravtansine

chemotherapy, +1 more type

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

~29 mi. (Guadalajara, Mexico, +112 more cities)

Hospital Civil De Guadalajara Juan I Menchaca

Non-Small Cell Lung Carcinoma

carboplatin, +5 more drugs

chemotherapy, +1 more type

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

~29 mi. (Guadalajara, Mexico, +180 more cities)

Exelixis Clinical Site #173

Prostate Adenocarcinoma

atezolizumab, +1 more drug

immunotherapy, +1 more type

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

~29 mi. (Guadalajara, Mexico, +184 more cities)

Actualidad Basada en la Investigación del Cáncer

RET Fusion

Non-Squamous Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

~29 mi. (Guadalajara, Mexico, +105 more cities)

Actualidad Basada en la Investigacion del Cancer ( Site 2903)

ATM Loss, +62 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib

targeted therapy

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

~34 mi. (Zapopan, Mexico, +247 more cities)

Local Institution

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

anthracycline, +4 more drugs

chemotherapy, +2 more types